Tevogen Bio Holdings (TVGN) Equity Average (2022 - 2026)
Tevogen Bio Holdings (TVGN) reported Equity Average of -$9.0 million for Q1 2026, down 25.59% on a YoY basis from -$12.1 million in Q1 2025, and down 12.57% quarter-over-quarter from -$8.0 million in Q4 2025.
Tevogen Bio Holdings (TVGN) Equity Average (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Equity Average for 5 years, with the latest figure at -$9.0 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 25.59% year-over-year to -$9.0 million; the trailing twelve-month figure through Mar 2026 stood at -$9.0 million (down 25.59% YoY), and the FY2025 full-year result was -$7.5 million, up 85.25% from the prior year.
- Equity Average for Q1 2026 stood at -$9.0 million, down from -$8.0 million in the prior quarter.
- The five-year high for Equity Average was -$6.4 million in Q4 2024, with the low at -$92.6 million in Q4 2023.
- Historically, Equity Average has averaged -$28.6 million across 5 years, with a median of -$14.2 million in 2022.
- Annual changes were most pronounced in 2023 — Equity Average plunged 519.03% — and 2024, when it surged 93.05%.
- Tevogen Bio Holdings' Equity Average stood at -$24.3 million in 2022, then plunged by 281.05% to -$92.6 million in 2023, then surged by 93.05% to -$6.4 million in 2024, then dropped by 24.83% to -$8.0 million in 2025, then dropped by 12.57% to -$9.0 million in 2026.
- The last three Equity Average figures came in at -$9.0 million (Q1 2026), -$8.0 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 516.41 Mn |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - | -9.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.04 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Sep 30, 2025 | -8.65 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Mar 31, 2025 | -7.20 Mn |
| Dec 31, 2024 | -6.43 Mn |
| Sep 30, 2024 | -6.93 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -50.12 Mn |
| Dec 31, 2023 | -92.61 Mn |
| Sep 30, 2023 | -88.84 Mn |
| Jun 30, 2023 | -75.80 Mn |
| Mar 31, 2023 | -49.33 Mn |
| Dec 31, 2022 | -24.30 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -14.15 Mn |
| Mar 31, 2022 | -14.24 Mn |